The economic burden of prostate cancer

BJU International

Volumn 108, Issue 6, 2011, Pages 806-813

  Roehrborn, Claus G ^a   Black, Libby K ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

costs; economic burden; prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONSULTATION; COST OF ILLNESS; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL CARE; HUMAN; ITALY; MEDICARE; NETHERLANDS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SPAIN; UNITED KINGDOM; UNITED STATES; WATCHFUL WAITING;

AUSTRALIA; CANADA; COST OF ILLNESS; DELIVERY OF HEALTH CARE; DRUG COSTS; EUROPE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MALE; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 80052083039     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10365.x     Document Type: Article

References (34)

1. Garcia M, Jemal A, Ward EM, et al,. Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta, GA, USA. Available at:. Accessed 22 December 2010
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
3. Lunenfeld B,. The ageing male: demographics and challenges. World J Urol 2002; 20: 11-6
4. Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO,. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 1996; 88: 1216-21 (Pubitemid 26302035)
5. Sedjo RL, Byers T, Barrera E Jr, et al,. A midpoint assessment of the American Cancer Society challenge goal to decrease cancer incidence by 25% between 1992 and 2015. CA Cancer J Clin 2007; 57: 326-40 (Pubitemid 350234399)
6. Taichman RS, Loberg RD, Mehra R, Pienta KJ,. The evolving biology and treatment of prostate cancer. J Clin Invest 2007; 117: 2351-61 (Pubitemid 47494332)
7. United States Department of Labor. Consumer Price Index. US Medical Care Services Bureau of Labor Statistics, Washington, DC, USA. Available from:. Accessed 1 September 2010
8. Bank of England. Interest and Exchange Rates. Bank of England, London, UK. Available at:. Accessed 1 September 2010
9. Chamberlain J, Melia J, Moss S, Brown J,. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997; 79 (Suppl. 3): 1-32
10. Marks GC, Pang G, Coyne T, Picton P,. Cancer Costs in Australia-the potential impact of dietary change. Australian Food and Nutrition Monitoring Unit, Commonwealth Department of Health and Aged Care, Canberra, ACT, Australia. Available at:. Accessed 1 September 2010
11. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ,. Current and future costs of cancer. Eur J Cancer 1994; 30A: 60-5 (Pubitemid 24058091)
12. National Cancer Institute. Cancer Trends Progress Report-2009/2010 Update. Costs of Cancer Care. Available at:. Accessed 23 December 2010
13. Lazzaro C, Gruppo Informale di Studio sugli aspetti Economico-Sanitari del Carcinoma Prostatico in Italia. [Managing patients with prostate cancer in Italy during the first year after diagnosis. A cost description based on a sample of 8 urological wards. Arch Ital Urol Androl 2003; 75: 138-49 [Article in Italian] (Pubitemid 37428991)
14. Fourcade RO, Benedict A, Black LK, Stokes ME, Alcaraz A, Castro R,. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int 2010; 105: 49-56
15. Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A,. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis 2009; 12: 355-60
16. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA,. The economic consequences of prostate and bladder cancer in the UK. BJU Int 2005; 95: 59-63 (Pubitemid 350020870)
17. Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P,. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010; 13: 278-84
18. Crawford ED, Black L, Eaddy M, Kruep EJ,. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 162-7
19. Centre for Economic Performance. Election Analysis 2010. The London School of Economics and Political Science, London, UK. Available at:. Accessed 19 July 2010
20. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML,. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008; 100: 888-97 (Pubitemid 351881955)
21. Corcoran AT, Peele PB, Benoit RM,. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology 2010; 76: 703-7
22. Yabroff KR, Lamont EB, Mariotto A, et al,. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100: 630-41
23. Public Health Agency of Canada. Economic Burden of Illness in Canada. Ottawa, ON, Canada: Policy Research Division, 1998. Available from:. Accessed June 2011
24. Krahn MD, Zagorski B, Laporte A, et al,. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int 2009; 105: 338-46
25. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917
26. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. World Health Organisation, International Agency for Research on Cancer, Lyon, France. Available at:. Accessed 22 December 2010
27. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
28. Vela Navarrete R,. Frans Debruyne Valedictory Lecture. A look into the future of Urology. Actas Urol Esp 2007; 31: 431-6
29. American Urological Association. Statement on early detection of prostate cancer: Update May 2006. AUA, Linthicum, MD, USA. Available at:. Accessed 7 April 2009
30. American Urological Association. Policy statement on early detection of prostate cancer: Update April 2009. AUA, Linthicum, MD, USA. Available at:. Accessed 1 September 2010
31. McNaughton-Collins M, Walker-Corkery E, Barry MJ,. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000. J Natl Cancer Inst Monogr 2004; 2004: 78-101
32. American Cancer Society. Global Cancer Facts & Figures 2008. American Cancer Society, Atlanta, GA, USA. Available at:. Accessed 23 December 2010
33. Thomas G, Jacobs KB, Yeager M, et al,. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5 (Pubitemid 351311773)
34. Kramer BS, Hagerty KL, Justman S, et al,. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009; 181: 1642-57